Research
Mixed
Metabolomic profiling (metabotyping) reveals that metabolic syndrome, obesity, T2DM, and CVDs share common metabolic signatures and pathways, suggesting that dietary interventions and pharmacologic treatments can target these shared traits.
Understanding that these diseases share metabolic roots allows for integrated treatment strategies, such as dietary changes that address insulin resistance and inflammation, benefiting multiple conditions simultaneously.
GoodQualifiesHIGH confidence
Metabolomic analysis to identify CMDs metabotypes revealed that they share similar metabolic signatures and metabolic pathways. These metabolic pathways may indicate the presence of insulin resistance, mitochondrial dysfunction, low-grade inflammation, and dysbiotic gut microbiota.
Why this rating
Based on pathway analyses from multiple studies.
Source
The metabolic signatures of cardiometabolic diseases: Does the shared metabotype offer new therapeutic targets?
Arwa M. Amin · Lifestyle Medicine · 2021
DOI 10.1002/lim2.25
narrative_reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin resistance (IR) and the resulting hyperinsulinemia constitute the primary shared pathogenic mechanism linking metabolic syndrome, obesity, and type 2 diabetes (T2DM), driving cardiovascular disease (CVD) risk through prothrombotic effects, endothelial dysfunction, and atherogenic dyslipidemia.Good
- Dysbiotic gut microbiota and its derived metabolites (such as TMAO, choline, and hippurate) are shared metabolic biomarkers across cardiometabolic diseases, contributing to inflammation, atherosclerosis, and insulin resistance.Good
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →